WEBINAR ON DEMAND
Duration: 1 hour

The vast array of antibody variants, including multispecific antibodies (msAb), bispecific antibodies (bsAb), antibody fragments (Fab, dAb, scFv), and antibody-drug conjugates (ADC) creates diversity as well as challenges. ADCs combine the advantage of the selectivity of a mAb with the potent cell-killing activity of a small cytotoxic molecule.

Join us to learn about the history of ADCs and discuss their current state in the marketplace. You'll discover how to harness their high selectivity, safety, and efficacy, plus:

• The mechanisms of action and safety considerations for ADCs
• The design of the antibody and the spacer-linker in ADCs
• Specificity, safety, functionality, Pharmacokinetic-Pharmacodynamic and stability in ADC development
• Cell line manufacturing facts, steps and bioreactor scale-up

SPEAKERS

Alper Uras
US & Canada Downstream Fast Trak Leader
Cytiva

Yuval Yarkoni, PhD, PMP
Molecular Immunologist